ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ...

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy productViGeneron is...

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV)...

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...